{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:26:44Z","timestamp":1790908004231,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2019M3A9E2061791"],"award-info":[{"award-number":["2019M3A9E2061791"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Contact-based pericellular interactions play important roles in cancer progression via juxtacrine signaling pathways. The present study revealed that hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), induced even in non-hypoxic conditions by cell-to-cell contact, was a critical cue responsible for the malignant characteristics of glioblastoma multiforme (GBM) cells through Notch1 signaling. Densely cultured GBM cells showed enhanced viability and resistance to temozolomide (TMZ) compared to GBM cells at a low density. Ablating Notch1 signaling by a \u03b3-secretase inhibitor or siRNA transfection resensitized resistant GBM cells to TMZ treatment and decreased their viability under dense culture conditions. The expression of HIF-1\u03b1 was significantly elevated in highly dense GBM cells even under non-hypoxic conditions. Atypical HIF-1\u03b1 expression was associated with the Notch1 signaling pathway in both GBM and glioblastoma stem cells (GSC). Proteasomal degradation of HIF-1\u03b1 was prevented by binding with Notch1 intracellular domain (NICD), which translocated to the nuclei of GBM cells. Silencing Notch1 signaling using a doxycycline-inducible Notch1 RNA-interfering system or treatment with chetomin, a HIF pathway inhibitor, retarded tumor development with a significant anti-cancer effect in a murine U251-xenograft model. Using GBM patient tissue microarray analysis, a significant increase in HIF-1\u03b1 expression was identified in the group with Notch1 expression compared to the group without Notch1 expression among those with positive HIF-1\u03b1 expression. Collectively, these findings highlight the critical role of cell-to-cell contact-dependent signaling in GBM progression. They provide a rationale for targeting HIF-1\u03b1 signaling even in a non-hypoxic microenvironment.<\/jats:p>","DOI":"10.1007\/s00018-022-04529-2","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T09:02:26Z","timestamp":1664701346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Atypical induction of HIF-1\u03b1 expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-0478","authenticated-orcid":false,"given":"Jungwhoi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuha","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Wook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungyeul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungsun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulhee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,2]]},"reference":[{"key":"4529_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","volume":"9","author":"TF Cloughesy","year":"2014","unstructured":"Cloughesy TF, Cavenee WK, Mischel PS (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9:1\u201325. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130324","journal-title":"Annu Rev Pathol"},{"key":"4529_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41578-019-0135-y","volume":"4","author":"KJ Wolf","year":"2019","unstructured":"Wolf KJ, Chen J, Coombes J, Aghi MK, Kumar S (2019) Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nat Rev Mater 4:651\u2013668. https:\/\/doi.org\/10.1038\/s41578-019-0135-y","journal-title":"Nat Rev Mater"},{"key":"4529_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41467-019-14036-x","volume":"11","author":"X Meng","year":"2020","unstructured":"Meng X, Zhao Y, Han B, Zha C, Zhang Y, Li Z, Wu P, Qi T, Jiang C, Liu Y, Cai J (2020) Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways. Nat Commun 11:594. https:\/\/doi.org\/10.1038\/s41467-019-14036-x","journal-title":"Nat Commun"},{"key":"4529_CR4","first-page":"911","volume":"29","author":"S Oshiro","year":"2009","unstructured":"Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T (2009) Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res 29:911\u2013917","journal-title":"Anticancer Res"},{"key":"4529_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, C. North American Brain Tumor and I. the National Cancer (2005)  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investig New Drugs 23:357\u2013361. https:\/\/doi.org\/10.1007\/s10637-005-1444-0","journal-title":"Investig New Drugs"},{"key":"4529_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00401-006-0186-1","volume":"113","author":"D Kita","year":"2007","unstructured":"Kita D, Yonekawa Y, Weller M, Ohgaki H (2007) PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113:295\u2013302. https:\/\/doi.org\/10.1007\/s00401-006-0186-1","journal-title":"Acta Neuropathol"},{"key":"4529_CR7","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, G. North Central Cancer Treatment (2005) Phase II trial of temsirolimus (CCI-779)\n in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294\u20135304. https:\/\/doi.org\/10.1200\/JCO.2005.23.622","journal-title":"J Clin Oncol"},{"key":"4529_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/glia.440150311","volume":"15","author":"O Bogler","year":"1995","unstructured":"Bogler O, Huang HJ, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia 15:308\u2013327. https:\/\/doi.org\/10.1002\/glia.440150311","journal-title":"Glia"},{"key":"4529_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1750-3639.2008.00225.x","volume":"19","author":"AJ Sievert","year":"2009","unstructured":"Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel JA (2009) Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 19:449\u2013458. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00225.x","journal-title":"Brain Pathol"},{"key":"4529_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1476-4598-9-135","volume":"9","author":"C Krakstad","year":"2010","unstructured":"Krakstad C, Chekenya M (2010) Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9:135. https:\/\/doi.org\/10.1186\/1476-4598-9-135","journal-title":"Mol Cancer"},{"key":"4529_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","volume":"1","author":"Y Ye","year":"2019","unstructured":"Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L (2019) Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat Metab 1:431\u2013444. https:\/\/doi.org\/10.1038\/s42255-019-0045-8","journal-title":"Nat Metab"},{"key":"4529_CR12","doi-asserted-by":"publisher","first-page":"11371","DOI":"10.1038\/ncomms11371","volume":"7","author":"E Bourseau-Guilmain","year":"2016","unstructured":"Bourseau-Guilmain E, Menard JA, Lindqvist E, Indira-Chandran V, Christianson HC, Cerezo-Magana M, Lidfeldt J, Marko-Varga G, Welinder C, Belting M (2016) Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. Nat Commun 7:11371. https:\/\/doi.org\/10.1038\/ncomms11371","journal-title":"Nat Commun"},{"key":"4529_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia \u2014 a key regulatory factor in tumour growth. Nat Rev Cancer 2:38\u201347. https:\/\/doi.org\/10.1038\/nrc704","journal-title":"Nat Rev Cancer"},{"key":"4529_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"J Pouyssegur","year":"2006","unstructured":"Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437\u2013443. https:\/\/doi.org\/10.1038\/nature04871","journal-title":"Nature"},{"key":"4529_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0092-8674(01)00518-9","volume":"107","author":"GL Semenza","year":"2001","unstructured":"Semenza GL (2001) HIF-1, O2, and the 3 PHDsCell 107:1\u20133. https:\/\/doi.org\/10.1016\/s0092-8674(01)00518-9","journal-title":"Cell"},{"key":"4529_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0304-419x(94)90003-5","volume":"1198","author":"W Birchmeier","year":"1994","unstructured":"Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1198:11\u201326. https:\/\/doi.org\/10.1016\/0304-419x(94)90003-5","journal-title":"Biochem Biophys Acta"},{"key":"4529_CR17","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1038\/onc.2008.226","volume":"27","author":"P Rizzo","year":"2008","unstructured":"Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L (2008) Rational targeting of notch signaling in cancer. Oncogene 27:5124\u20135131. https:\/\/doi.org\/10.1038\/onc.2008.226","journal-title":"Oncogene"},{"key":"4529_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","volume":"16","author":"A Pannuti","year":"2010","unstructured":"Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L (2010) Targeting notch to target cancer stem cells. Clin Cancer Res 16:3141\u20133152. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2823","journal-title":"Clin Cancer Res"},{"key":"4529_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","volume":"12","author":"N Takebe","year":"2015","unstructured":"Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP (2015) Targeting Notch, Hedgehog, and WNT pathways in cancer stem cells: clinical update\n. Nat Rev Clin Oncol 12:445\u2013464. https:\/\/doi.org\/10.1038\/nrclinonc.2015.61","journal-title":"Nat Rev Clin Oncol"},{"key":"4529_CR20","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770\u2013776. https:\/\/doi.org\/10.1126\/science.284.5415.770","journal-title":"Science"},{"key":"4529_CR21","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1038\/onc.2008.227","volume":"27","author":"J Dufraine","year":"2008","unstructured":"Dufraine J, Funahashi Y, Kitajewski J (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27:5132\u20135137. https:\/\/doi.org\/10.1038\/onc.2008.227","journal-title":"Oncogene"},{"key":"4529_CR22","doi-asserted-by":"publisher","first-page":"12760","DOI":"10.1038\/s41598-017-13023-w","volume":"7","author":"J Lee","year":"2017","unstructured":"Lee J, Lee J, Yun JH, Choi C, Cho S, Kim SJ, Kim JH (2017) Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A. Sci Rep 7:12760. https:\/\/doi.org\/10.1038\/s41598-017-13023-w","journal-title":"Sci Rep"},{"key":"4529_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00527-3","author":"J Lee","year":"2020","unstructured":"Lee J, Lee J, Kim JH (2020). Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer. Cell Oncol. https:\/\/doi.org\/10.1007\/s13402-020-00527-3","journal-title":"Cell Oncol"},{"key":"4529_CR24","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41598-019-39628-x","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Lee J, Choi C, Kim JH (2019) Blockade of integrin \u03b13 attenuates human pancreatic cancer via inhibition of EGFR signalling. Sci Rep 9:2793. https:\/\/doi.org\/10.1038\/s41598-019-39628-x","journal-title":"Sci Rep"},{"key":"4529_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.canlet.2011.05.026","volume":"309","author":"J Lee","year":"2011","unstructured":"Lee J, Lee J, Yu H, Choi K, Choi C (2011) Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett 309:145\u2013150. https:\/\/doi.org\/10.1016\/j.canlet.2011.05.026","journal-title":"Cancer Lett"},{"key":"4529_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2011.12.014","volume":"318","author":"J Lee","year":"2012","unstructured":"Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, Choi C (2012) Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer Lett 318:221\u2013225. https:\/\/doi.org\/10.1016\/j.canlet.2011.12.014","journal-title":"Cancer Lett"},{"key":"4529_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1215\/S1152851704001115","volume":"7","author":"B Kaur","year":"2005","unstructured":"Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134\u2013153. https:\/\/doi.org\/10.1215\/S1152851704001115","journal-title":"Neuro Oncol"},{"key":"4529_CR28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41401-020-00551-x","volume":"42","author":"T Sun","year":"2021","unstructured":"Sun T, Xu YJ, Jiang SY, Xu Z, Cao BY, Sethi G, Zeng YY, Kong Y, Mao XL (2021) Suppression of the USP10\/CCND1 axis induces glioblastoma cell apoptosis. Acta Pharmacol Sin 42:1338\u20131346. https:\/\/doi.org\/10.1038\/s41401-020-00551-x","journal-title":"Acta Pharmacol Sin"},{"key":"4529_CR29","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/carcin\/bgu008","volume":"35","author":"SK Hwang","year":"2014","unstructured":"Hwang SK, Baker AR, Young MR, Colburn NH (2014) Tumor suppressor PDCD4 inhibits NF-\u03baB-dependent transcription in human glioblastoma cells by direct interaction with p65. Carcinogenesis 35:1469\u20131480. https:\/\/doi.org\/10.1093\/carcin\/bgu008","journal-title":"Carcinogenesis"},{"key":"4529_CR30","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMc086380","volume":"359","author":"MA Meyer","year":"1850","unstructured":"Meyer MA (1850) N Engl J Med 359:2008. https:\/\/doi.org\/10.1056\/NEJMc086380 (author reply 1850)","journal-title":"N Engl J Med"},{"key":"4529_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, R. European Organisation for, T. Treatment of Cancer Brain, G. Radiotherapy and G. National Cancer Institute of Canada Clinical Trials (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"4529_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1541-7786.MCR-06-0085","volume":"4","author":"M Puputti","year":"2006","unstructured":"Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, Paetau A, Joensuu H, Nupponen NN (2006) Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas. Mol Cancer Res MCR 4:927\u2013934. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0085","journal-title":"Mol Cancer Res MCR"},{"key":"4529_CR33","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624\u20131636. https:\/\/doi.org\/10.1200\/JCO.2003.05.063","journal-title":"J Clin Oncol"},{"key":"4529_CR34","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1038\/sj.onc.1204972","volume":"20","author":"EA Sheta","year":"2001","unstructured":"Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D (2001) Cell density mediated pericellular hypoxia leads to induction of HIF-1\u03b1 via nitric oxide and Ras\/MAP kinase mediated signaling pathways. Oncogene 20:7624\u20137634. https:\/\/doi.org\/10.1038\/sj.onc.1204972","journal-title":"Oncogene"},{"key":"4529_CR35","first-page":"251","volume":"50","author":"A Chrastina","year":"2003","unstructured":"Chrastina A (2003) Neoplasma 50:251\u2013256","journal-title":"Neoplasma"},{"key":"4529_CR36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"4529_CR37","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1158\/0008-5472.CAN-10-1378","volume":"70","author":"CA Gilbert","year":"2010","unstructured":"Gilbert CA, Daou MC, Moser RP, Ross AH (2010) \u03b3-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Can Res 70:6870\u20136879. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1378","journal-title":"Can Res"},{"key":"4529_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/cdd.2008.21","volume":"15","author":"EB Rankin","year":"2008","unstructured":"Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15:678\u2013685. https:\/\/doi.org\/10.1038\/cdd.2008.21","journal-title":"Cell Death Differ"},{"key":"4529_CR39","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/leu.2011.122","volume":"25","author":"SK Martin","year":"2011","unstructured":"Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC (2011) The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 25:1533\u20131542. https:\/\/doi.org\/10.1038\/leu.2011.122","journal-title":"Leukemia"},{"key":"4529_CR40","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/onc.2009.441","volume":"29","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625\u2013634. https:\/\/doi.org\/10.1038\/onc.2009.441","journal-title":"Oncogene"},{"key":"4529_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2017.10.003","volume":"113","author":"TL Place","year":"2017","unstructured":"Place TL, Domann FE, Case AJ (2017) Limitations of oxygen delivery to cells in culture: an underappreciated problem in basic and translational research. Free Radical Biol Med 113:311\u2013322. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.10.003","journal-title":"Free Radical Biol Med"},{"key":"4529_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/cdd.2011.95","volume":"19","author":"L Qiang","year":"2012","unstructured":"Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, Zhao L, Chen FH, Wang XT, You QD, Guo QL (2012) HIF-1\u03b1 is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 19:284\u2013294. https:\/\/doi.org\/10.1038\/cdd.2011.95","journal-title":"Cell Death Differ"},{"key":"4529_CR43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3892\/ijo.2015.3056","volume":"47","author":"Q Tian","year":"2015","unstructured":"Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang X, An R (2015) Overexpression of hypoxia-inducible factor 1\u03b1 induces migration and invasion through Notch signaling. Int J Oncol 47:728\u2013738. https:\/\/doi.org\/10.3892\/ijo.2015.3056","journal-title":"Int J Oncol"},{"key":"4529_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","volume":"15","author":"J Schodel","year":"2019","unstructured":"Schodel J, Ratcliffe PJ (2019) Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol 15:641\u2013659. https:\/\/doi.org\/10.1038\/s41581-019-0182-z","journal-title":"Nat Rev Nephrol"},{"key":"4529_CR45","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello JE, Jovin IS, Huang Y (2007) Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 80:51\u201360","journal-title":"Yale J Biol Med"},{"key":"4529_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-019-00326-1","author":"ORM Bagshaw","year":"2019","unstructured":"Bagshaw ORM, De Lange M, Renda S, Valente AJF, Stuart JA (2019). Hypoxio: a simple solution to preventing pericellular hypoxia in cell monolayers growing at physiological oxygen levels. Cytotechnology. https:\/\/doi.org\/10.1007\/s10616-019-00326-1","journal-title":"Cytotechnology"},{"key":"4529_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1095\/biolreprod.113.113068","volume":"91","author":"P Marsters","year":"2014","unstructured":"Marsters P, Alhamdan R, Campbell BK (2014) Cell density-mediated pericellular hypoxia and the local dynamic regulation of VEGF-A splice variants in ovine ovarian granulosa cells1. Biol Reprod 91:35. https:\/\/doi.org\/10.1095\/biolreprod.113.113068","journal-title":"Biol Reprod"},{"key":"4529_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152382","volume":"11","author":"M Weiszenstein","year":"2016","unstructured":"Weiszenstein M, Pavlikova N, Elkalaf M, Halada P, Seda O, Trnka J, Kovar J, Polak J (2016) The effect of pericellular oxygen levels on proteomic profile and lipogenesis in 3t3-l1 differentiated preadipocytes cultured on gas-permeable cultureware. PLoS ONE 11:e0152382. https:\/\/doi.org\/10.1371\/journal.pone.0152382","journal-title":"PLoS ONE"},{"key":"4529_CR49","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1038\/s41388-020-1302-8","volume":"39","author":"V Adamski","year":"2020","unstructured":"Adamski V, Hattermann K, Kubelt C, Cohrs G, Lucius R, Synowitz M, Sebens S, Held-Feindt J (2020) Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1. Oncogene 39:4421\u20134435. https:\/\/doi.org\/10.1038\/s41388-020-1302-8","journal-title":"Oncogene"},{"key":"4529_CR50","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834\u2013846. https:\/\/doi.org\/10.1038\/nrc2256","journal-title":"Nat Rev Cancer"},{"key":"4529_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djj068","volume":"98","author":"GN Naumov","year":"2006","unstructured":"Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316\u2013325. https:\/\/doi.org\/10.1093\/jnci\/djj068","journal-title":"J Natl Cancer Inst"},{"key":"4529_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044395","volume":"7","author":"R Satchi-Fainaro","year":"2012","unstructured":"Satchi-Fainaro R, Ferber S, Segal E, Ma L, Dixit N, Ijaz A, Hlatky L, Abdollahi A, Almog N (2012) Prospective identification of glioblastoma cells generating dormant tumors. PLoS ONE 7:e44395. https:\/\/doi.org\/10.1371\/journal.pone.0044395","journal-title":"PLoS ONE"},{"key":"4529_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.819216","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Huang W, Chen H, Jiang H, Yang C, Shen S, Cui Y, Dong G, Ren X, Lin S (2022) T2\/FLAIR abnormity could be the sign of glioblastoma dissemination. Front Neurol 13:819216. https:\/\/doi.org\/10.3389\/fneur.2022.819216","journal-title":"Front Neurol"},{"key":"4529_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11060-016-2193-y","volume":"129","author":"A Lasocki","year":"2016","unstructured":"Lasocki A, Gaillard F, Tacey MA, Drummond KJ, Stuckey SL (2016) The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma. J Neurooncol 129:471\u2013478. https:\/\/doi.org\/10.1007\/s11060-016-2193-y","journal-title":"J Neurooncol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04529-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T10:34:22Z","timestamp":1667039662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04529-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4529"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04529-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CC is the founder and shareholder of ILIAS Biologics, Inc. EK and KChoi are minor shareholders of ILIAS Biologics, Inc. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"537"}}